Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.

Abstract:

:Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer severe side effects from particular chemotherapy drugs. These observations have resulted in a concerted research effort to identify markers of chemotherapy efficacy and toxicity. Here we review the evidence for using molecular markers to individualize chemotherapy treatment in colorectal cancer.

authors

Braun MS,Quirke P,Seymour MT

doi

10.1586/14737140.7.4.489

subject

Has Abstract

pub_date

2007-04-01 00:00:00

pages

489-501

issue

4

eissn

1473-7140

issn

1744-8328

journal_volume

7

pub_type

杂志文章,评审
  • Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy.

    abstract::Renal neoplasms exhibit a wide spectrum of molecular characteristics that are closely associated with their diverse morphologic manifestations and clinical behaviors. A wealth of information has been garnered via methodology ranging from classical cytogenetics to FISH and gene expression profiling; however, the exact ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.72

    authors: Cheng L,Williamson SR,Zhang S,Maclennan GT,Montironi R,Lopez-Beltran A

    更新日期:2010-06-01 00:00:00

  • The evolving role of receptors as predictive biomarkers for metastatic breast cancer.

    abstract:INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1552138

    authors: Martínez-Pérez C,Turnbull AK,Dixon JM

    更新日期:2019-02-01 00:00:00

  • Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.

    abstract::Pegylated liposomal doxorubicin (PLD) was first approved for platinum-refractory ovarian cancer in 1999 and then received full approval for platinum-sensitive recurrent disease in 2005 by the US FDA. PLD remains an important therapeutic tool in the management of recurrent ovarian cancer in 2012. Phase-II and III clini...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.187

    authors: Rakowski JA,Ahmad S,Holloway RW

    更新日期:2012-01-01 00:00:00

  • Cladribine in indolent non-Hodgkin's lymphoma.

    abstract::Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.535

    authors: Sigal DS,Saven A

    更新日期:2008-04-01 00:00:00

  • Capecitabine in the treatment of colorectal cancer.

    abstract::Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.6.803

    authors: Kelly C,Cassidy J

    更新日期:2007-06-01 00:00:00

  • Management of Merkel cell carcinoma.

    abstract::Merkel cell carcinoma is an uncommon cutaneous malignancy. Although it is rare, Merkel cell carcinoma has been described as the most malignant primary skin tumor. It is therefore important that once diagnosed, Merkel cell carcinoma is treated appropriately. The aim of this short review is to provide a summary of the a...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.3.441

    authors: Plunkett TA,Subrumanian R,Leslie MD,Harper PG

    更新日期:2001-10-01 00:00:00

  • Update on genetic predisposition to breast cancer.

    abstract::It has been evident for some time that individuals from some families exhibit a genetic predisposition to breast cancer. Since the discovery of the first breast cancer susceptibility gene, BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led to the ide...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.38

    authors: Ahmed M,Lalloo F,Evans DG

    更新日期:2009-08-01 00:00:00

  • Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.

    abstract:BACKGROUND:Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens. METHOD...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2015.1061937

    authors: Vincenzi B,Imperatori M,Picardi A,Vespasiani Gentilucci U,Gallo P,Fausti V,Spalato Ceruso M,Santini D,Tonini G

    更新日期:2015-01-01 00:00:00

  • Improving the accuracy in prognosis for Burkitt lymphoma patients.

    abstract::A recent population-based study on 2000 adult patients with Burkitt lymphoma presented a novel score that takes into account age, race and clinical stage to prognosticate survival. The outcome of patients with Burkitt lymphoma has improved in the last decade, likely due to intensive chemotherapy regimens and anti-CD20...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.866042

    authors: Castillo JJ,Nadeem O

    更新日期:2014-02-01 00:00:00

  • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.

    abstract:INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1247699

    authors: Weinberger V,Bednarikova M,Cibula D,Zikan M

    更新日期:2016-12-01 00:00:00

  • End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.

    abstract::In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological pattern...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.164

    authors: Franceschi E,Agati R,Brandes AA

    更新日期:2011-11-01 00:00:00

  • The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.

    abstract::The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemotherapy have been push...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2016.1162099

    authors: Kell J

    更新日期:2016-01-01 00:00:00

  • Squamous cell carcinoma of the vulva: a review of present management and future considerations.

    abstract:INTRODUCTION:Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly en...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1538797

    authors: Buchanan T,Mutch D

    更新日期:2019-01-01 00:00:00

  • Therapeutic endoscopy and endoscopic ultrasound for gastrointestinal malignancies.

    abstract::Gastrointestinal endoscopy and endoscopic ultrasound not only provide strategies to diagnose and stage malignancy, but also to administer palliative and definitive care. Options for anticancer therapy include endoscopic mucosal resection, photodynamic therapy, thermal therapy, self-expanding metal stents and recently,...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.4.705

    authors: Wong RF,Bhutani MS

    更新日期:2005-08-01 00:00:00

  • Clinical implications of lung neuroendocrine neoplasm classification.

    abstract:INTRODUCTION:Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell carcinoma and large-cell NE carcinoma. This classification is the current basis for orienting the daily practi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1862654

    authors: Metovic J,Barella M,Harari S,Pattini L,Albini A,Sonzogni A,Veronesi G,Papotti M,Pelosi G

    更新日期:2020-12-24 00:00:00

  • Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.

    abstract::According to computed tomography image analysis, skeletal muscle (SM) and adipose tissue areas vary widely in patients with the same body mass index or the same body surface area. Body composition variables such as SM mass, SM density and subcutaneous and visceral adipose tissue have shown value as potential independe...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.866040

    authors: Antoun S,Lanoy E,Albiges-Sauvin L,Escudier B

    更新日期:2014-03-01 00:00:00

  • Ductal carcinoma in situ: treatment or active surveillance?

    abstract::Ductal carcinoma-in situ (DCIS) is a non-obligate precursor for invasive breast cancer and concern exists regarding the potential for overdiagnosis and overtreatment as the natural history of DCIS progression to invasive breast cancer may never occur or take decades in some cases. Preoperative systemic therapy window ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1043897

    authors: Kuerer HM

    更新日期:2015-01-01 00:00:00

  • Pembrolizumab for the treatment of gastric cancer.

    abstract:INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immun...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1526084

    authors: Kamath SD,Kalyan A,Benson AB 3rd

    更新日期:2018-12-01 00:00:00

  • Antineoplastic therapy-induced pulmonary toxicity.

    abstract::Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.817684

    authors: Sadowska AM,Specenier P,Germonpre P,Peeters M

    更新日期:2013-08-01 00:00:00

  • Advances in diagnosis and management of oligodendroglioma.

    abstract::Oligodendrogliomas are primary brain tumors, genetically characterized by chromosomal alterations in the 1p and 19q. Recent clinical trials have shown that oligodendrogliomas are sensitive to PCV chemotherapy with 60-65% of patients responding and median response duration of 1-1.5 years. The response rate in mixed oli...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.5.520

    authors: Hussein MR,Baidas S

    更新日期:2002-10-01 00:00:00

  • Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

    abstract::This review summarizes the safety of sorafenib, an oral multikinase inhibitor, focusing on the randomized, placebo-controlled, Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) in renal cell carcinoma, which formed the basis of the approval of sorafenib. Similar to other targeted agents, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1193

    authors: Hutson TE

    更新日期:2007-09-01 00:00:00

  • Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review.

    abstract::Introduction: Surgical treatment of thyroid cancer has become less aggressive but for many patients, the threshold for performing total thyroidectomy (TT), as opposed to thyroid lobectomy (TL), has remained unclear. Current American Thyroid Association (ATA) guidelines encourage more individualization of treatment opt...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850280

    authors: Guo MY,Wiseman JJ,Wiseman SM

    更新日期:2020-12-15 00:00:00

  • Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.

    abstract::The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.5.865

    authors: Espinoza-Delgado I,Childs RW

    更新日期:2004-10-01 00:00:00

  • Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

    abstract::Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clini...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.848065

    authors: Quinn DI,Vaishampayan U,Higano CS,Lin DW,Shore ND,Beer TM

    更新日期:2014-01-01 00:00:00

  • Darbepoetin alfa: potential role in managing anemia in cancer patients.

    abstract::Anemia in cancer patients is frequent but often under-recognized and under-treated. This may be related to misconceptions about the impact of anemia on cancer patients and ill-defined guidelines for treatment, as well as the inadequacies of current therapy. Darbepoetin alfa, a novel erythropoiesis-stimulating protein ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.4.377

    authors: Pirker R,Smith R

    更新日期:2002-08-01 00:00:00

  • Screening for ovarian cancer.

    abstract::Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.1.55

    authors: Lewis S,Menon U

    更新日期:2003-02-01 00:00:00

  • Current and emerging treatments in the management of castration-resistant prostate cancer.

    abstract::Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.59

    authors: Shapiro D,Tareen B

    更新日期:2012-07-01 00:00:00

  • Fertility preservation in women with CNS tumors.

    abstract:INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1316195

    authors: Tosoni A,Balestrini D,Brandes AA

    更新日期:2017-05-01 00:00:00

  • Prodrugs for targeted cancer therapy.

    abstract::Introduction: Prodrugs have been used to improve the selectivity and efficacy of cancer therapy by targeting unique abnormal markers that are overexpressed by cancer cells and are absent in normal tissues. In this context, different strategies have been exploited and new ones are being developed each year. Areas cover...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1615890

    authors: Souza C,Pellosi DS,Tedesco AC

    更新日期:2019-06-01 00:00:00

  • Benefits of laparoscopic prostate-sparing radical cystectomy.

    abstract:PURPOSE:Prostate-sparing radical cystectomy has been described in the literature and has proven to be a promising procedure owing to the continence and erectile function results without necessarily compromising the oncologic outcome in selected patients. TECHNIQUE POINTS:A transperitoneal approach is used. Lymph node ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.21

    authors: Rozet F,Harmon J,Arroyo C,Cathelineau X,Barret E,Vallancien G

    更新日期:2006-01-01 00:00:00